article thumbnail

Governor’s 2025-26 May Revision Proposes Major Cuts to Healthcare and Undermines Medi-Cal Expansion Commitments

California Academy of Family Physicians (CAFP)

However, for individuals who do not qualify for federal Medicaid funding—such as most undocumented immigrants—the federal government does not provide matching funds, even when those individuals meet income eligibility requirements. The asset limit for a household would be $2,000 for an individual and $3,000 per couple.

article thumbnail

The Rising Tide of Medical Waste: One Model for Improvement

My Green Doctor

The breadth of services provided by modern day medicine is profound. Video recordings were taken as providers administered perioperative routine eyedrops to patients and the eyedrop bottle tips were cultured to assess microbial growth. Reducing waste can save money for practices and operating rooms, and benefit the environment.

Medical 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Takes Another Small Step to Increase Naloxone Access

FDA Law Blog

Most states have some form of naloxone standing order that allows a healthcare provider to write a prescription that covers a large group of people rather than just an individual patient. syringes), to any individual without a patient-specific prescription. syringes), to any individual without a patient-specific prescription.

article thumbnail

Why, Who, When, Where and More: New Draft Guidance on Notifying FDA about Discontinuance or Interruption in Manufacturing

FDA Law Blog

The draft guidance provides recommendations for applicants and manufacturers about the requirements for notifications about production changes of certain finished drugs and biological products and certain active pharmaceutical ingredients (API), and outlines information FDA would like to receive in addition to the requirements.

article thumbnail

Does the Drug Shortage White Paper Fall Short?

FDA Law Blog

Department of Health and Human Services (HHS) recently published a White Paper on Policy Considerations to Prevent Drug Shortages and Mitigate Supply Chain Vulnerabilities in the United States —with input from several HHS stakeholders, including FDA, CMS, and the Administration for Strategic Preparedness and Response.

article thumbnail

FDA Moves Beyond COVID-19, But Impacts on COVID-19 Era Clinical Trials Remain

FDA Law Blog

In general, both of these guidances provide recommendations for sponsors to consider and analyze when a disaster (e.g., For example, a disaster or public health emergency may lead to clinical trial disruptions via population quarantines, travel restrictions, various interruptions to the supply chain, and other logistical issues.

Clinic 64
article thumbnail

Is 2023 the Year for OTC Naloxone?

FDA Law Blog

sales of naloxone from a wholesale distributor to a harm reduction program) from certain requirements under the Drug Supply Chain Security Act. Many states already have standing orders that allow for the dispensing of naloxone without an individual prescription and other public health initiatives to increase naloxone access.